IN2014DN10734A - - Google Patents

Info

Publication number
IN2014DN10734A
IN2014DN10734A IN10734DEN2014A IN2014DN10734A IN 2014DN10734 A IN2014DN10734 A IN 2014DN10734A IN 10734DEN2014 A IN10734DEN2014 A IN 10734DEN2014A IN 2014DN10734 A IN2014DN10734 A IN 2014DN10734A
Authority
IN
India
Prior art keywords
subject
coq1o
coenzyme
failed
administration
Prior art date
Application number
Inventor
John Patrick Mccook
Paul Y Song
Niven Rajin Narain
Ines Macias-Perez
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Llc filed Critical Berg Llc
Publication of IN2014DN10734A publication Critical patent/IN2014DN10734A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention provides methods and compositions for treatment of a subject with a solid tumor comprising administration of Coenzyme Q10 (CoQ1O) particularly when the subject has failed at least one prior chemotherapeutic regimen.
IN10734DEN2014 2012-06-01 2013-05-31 IN2014DN10734A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261654245P 2012-06-01 2012-06-01
PCT/US2013/043785 WO2013181639A1 (en) 2012-06-01 2013-05-31 Treatment of solid tumors using coenzyme q10

Publications (1)

Publication Number Publication Date
IN2014DN10734A true IN2014DN10734A (en) 2015-09-04

Family

ID=49673946

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10734DEN2014 IN2014DN10734A (en) 2012-06-01 2013-05-31

Country Status (17)

Country Link
US (3) US20140017317A1 (en)
EP (1) EP2854528B8 (en)
JP (3) JP6352905B2 (en)
KR (2) KR20200118233A (en)
CN (1) CN104507308A (en)
AU (2) AU2013267166A1 (en)
BR (1) BR112014029954A2 (en)
CA (2) CA2875150C (en)
EA (1) EA032345B1 (en)
ES (1) ES2761449T3 (en)
HK (1) HK1208995A1 (en)
IL (1) IL236008B (en)
IN (1) IN2014DN10734A (en)
MX (2) MX369768B (en)
NZ (1) NZ702369A (en)
SG (1) SG11201407880QA (en)
WO (1) WO2013181639A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011011958A (en) 2009-05-11 2012-02-13 Berg Biosystems Llc Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers.
ES2762451T3 (en) 2011-04-04 2020-05-25 Berg Llc Treatment of tumors of the central nervous system with coenzyme Q10
MX369768B (en) * 2012-06-01 2019-11-21 Berg Llc Treatment of solid tumors using coenzyme q10.
CN113797343A (en) * 2013-04-08 2021-12-17 博格有限责任公司 Treatment of cancer using coenzyme Q10 combination therapy
WO2015035094A1 (en) 2013-09-04 2015-03-12 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
US9996463B2 (en) * 2015-11-10 2018-06-12 International Business Machines Corporation Selection and placement of volumes in a storage system using stripes
US20170189350A1 (en) * 2015-11-16 2017-07-06 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
US20170255565A1 (en) * 2016-03-02 2017-09-07 Intel Corporation Method and apparatus for providing a contiguously addressable memory region by remapping an address space
WO2018005412A1 (en) * 2016-06-28 2018-01-04 Tien Yang Der Chemoprotective/chemoactive nanodroplets and methods of use thereof
JP7173992B2 (en) 2017-05-17 2022-11-17 バーグ エルエルシー Use of coenzyme Q10 preparations in the treatment and prevention of epidermolysis bullosa
WO2023099436A1 (en) * 2021-12-01 2023-06-08 Gambro Lundia Ab New dialysis fluid

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
US8932649B2 (en) * 2003-11-14 2015-01-13 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds
KR20160106194A (en) * 2004-01-22 2016-09-09 유니버시티 오브 마이애미 Topical co-enzyme q10 formulations and methodns of use
JPWO2008069276A1 (en) * 2006-12-06 2010-03-25 株式会社カネカ Cancer therapeutic agent and carcinogenesis inhibitor
EP2136787B1 (en) 2007-03-22 2019-08-21 Berg LLC Topical formulations having enhanced bioavailability
US7732491B2 (en) * 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
EP4074344A1 (en) 2007-12-04 2022-10-19 Arbutus Biopharma Corporation Targeting lipids
US8247435B2 (en) * 2009-02-19 2012-08-21 Thornthwaite Jerry T Formulations for treating human and animal diseases
MX2011011958A (en) * 2009-05-11 2012-02-13 Berg Biosystems Llc Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers.
ES2664793T3 (en) 2010-03-12 2018-04-23 Berg Llc Intravenous formulations of coenzyme Q10 (CoQ10) and methods of use thereof
CA2839270C (en) 2011-06-17 2018-09-18 Berg Llc Inhalable liposomal pharmaceutical compositions
MX369768B (en) 2012-06-01 2019-11-21 Berg Llc Treatment of solid tumors using coenzyme q10.

Also Published As

Publication number Publication date
MX369768B (en) 2019-11-21
KR20150022932A (en) 2015-03-04
MX2019013776A (en) 2020-01-30
CA3090268A1 (en) 2013-12-05
CN104507308A (en) 2015-04-08
US20170216223A1 (en) 2017-08-03
IL236008A0 (en) 2015-02-01
CA2875150A1 (en) 2013-12-05
AU2017202567B2 (en) 2019-06-13
US20220096399A1 (en) 2022-03-31
EA201492187A1 (en) 2015-05-29
SG11201407880QA (en) 2014-12-30
MX2014014492A (en) 2015-05-12
EA032345B1 (en) 2019-05-31
CA2875150C (en) 2020-10-27
EP2854528A1 (en) 2015-04-08
NZ702369A (en) 2016-12-23
KR102163948B1 (en) 2020-10-12
EP2854528B8 (en) 2019-10-23
EP2854528A4 (en) 2016-03-09
JP2015518056A (en) 2015-06-25
AU2013267166A1 (en) 2014-12-18
JP6352905B2 (en) 2018-07-04
US20140017317A1 (en) 2014-01-16
JP7225167B2 (en) 2023-02-20
JP2020183440A (en) 2020-11-12
EP2854528B1 (en) 2019-09-18
ES2761449T3 (en) 2020-05-19
WO2013181639A8 (en) 2014-12-31
JP2018168164A (en) 2018-11-01
HK1208995A1 (en) 2016-03-24
KR20200118233A (en) 2020-10-14
BR112014029954A2 (en) 2017-06-27
WO2013181639A1 (en) 2013-12-05
AU2017202567A1 (en) 2017-05-11
IL236008B (en) 2018-08-30

Similar Documents

Publication Publication Date Title
IN2014DN10734A (en)
IL246544A0 (en) Compounds for treating patients with ros1 mutant cancer cells
UA116196C2 (en) Synthetic apelin mimetics for the treatment of heart failure
MX2019014986A (en) Methods of treatment of cancer by continuous infusion of coenzyme q10.
MX338015B (en) Compositions comprising a shelf-life stability component.
EP2809385A4 (en) Valved enteral administration assembly
IL223889B (en) Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
IL243927A0 (en) Digestive enzyme composition suitable for enteral administration
EP3132033A4 (en) Beta-lactamases with improved properties for therapy
EP3415159A4 (en) Pretreatment drug for t cell infusion therapy for immune-checkpoint inhibitor-resistant tumor
AU2012240222A8 (en) Methods of treating central nervous system tumors
EP3256133A4 (en) Intravenous infusion dosage form
EP3135293A4 (en) Agent for preventing or ameliorating diabetes
EP2982752A4 (en) Glucuronyl transferase, gene encoding same, and use thereof
WO2014147503A3 (en) Anti-bag3 antibodies for therapeutic use
GB2517634B (en) Connection arrangements, pivots and mechanisms
EP3318320A4 (en) Graphite group, carbon particles containing said graphite group
EP3041492A4 (en) INHIBITING INTERACTION BETWEEN HIF-1alfa AND P300/CBP WITH HYDROGEN BOND SURROGATE-BASED HELICES
MX2023003000A (en) Modified release formulations of viloxazine.
EP2836217A4 (en) Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents
ZA201802926B (en) Electrocatalyst for the reduction of oxygen
UA74355U (en) Method for preventing postpartum bleeding in patients with history of recurrent miscarriage
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
UA84204U (en) Method for immunocorrection of patients with chickenpox and immunodeficient state
AU351462S (en) Racking connector clip